Background: Population-based studies of adverse events are scarce. Our objective was to evaluate chemotherapyassociated adverse events among elderly colorectal cancer (CRC) patients treated in the community. Results: Of 46 692 patients assessed, 36 137 (77.4%) received no i.v. chemotherapy, 5472 (11.7%) received fluorouracil (5-FU) alone, 2284 (4.9%) received oxaliplatin-containing regimens, 1306 (2.8%) received bevacizumabcontaining regimens but without oxaliplatin, and 1493 (3.2%) received other chemotherapy. Symptoms and laboratory test abnormalities were commonly found in elderly, even in those who had not received any i.v. chemotherapy. The addition of i.v. chemotherapy was associated with higher incidences of adverse events. Oxaliplatin-based regimens led to higher incidences in nausea, neutropenia, and neuropathy compared with 5-FU alone. Patients aged ‡70 years (n = 37 601, 80.5%) tended to experience higher rates of certain adverse events, including infection, anemia, delirium, and heart disease than patients aged 65-69 years (n = 9091, 19.5%).
introduction
An estimated 142 570 new cases of large bowel cancer will occur in the United States in 2010, of which 102 900 are colon cancers; the remainders arise in the rectum [1] . The median age at diagnosis is 71. Approximately 70% of cases develop in patients over the age of 65. Fluorouracil (5-FU)-based chemotherapy improved survival in elderly patients both as adjuvant chemotherapy and palliative chemotherapy [2] [3] [4] [5] . Adding newer agents (oxaliplatin, irinotecan, and bevacizumab) to 5-FU-based chemotherapy resulted in additional survival benefits in elderly patients with metastatic cancer [6] [7] [8] . On the other hand, oxaliplatin-based adjuvant chemotherapy improved survival only in younger patients but not in elderly ones (age ‡70) after a 6-year long-term follow-up in phase III clinical trials [9, 10] . Subgroup analysis for elderly patients with colorectal cancer (CRC) had been conducted from randomized clinical trials and pool analysis and showed that older patients experienced an increased incidence of adverse events but showed an overall manageable toxicity profile from clinical trials using 5-FU [2, 3] , capecitabine [11] , oxaliplatin [6] , irinotecan [7] , and bevacizumab [12] [13] [14] [15] .
However, it should be noted that patients with CRC enrolled in clinical trials are much younger and fitter than those from the community [16] . Patients ‡65 years of age were underrepresented in these studies of treatment of CRC [16] . Studies on various adverse events associated with chemotherapy among elderly CRC patients in the community are scarce and are especially rare in regard to newer agents approved by the Food and Drug Administration after 2003. Kahn et al. [17] reported a population-based study on patients with stage III colon cancer using 5-FU-based and oxaliplatincontaining chemotherapy. However, various side-effects were not reported in detail, and their population did not include patients with metastatic disease.
The purpose of this study is to evaluate the use of chemotherapy and its association with some selected adverse events or toxic effects among elderly patients from a large population-based database [the Surveillance, Epidemiology, and End Results (SEER)and Medicare-linked database] between the years 2003-2005 when several newer chemotherapy agents had been approved for use in CRC in the USA market.
patients and methods data source
This retrospective study was conducted using the National Cancer Institute's SEER and Medicare-linked database, the comprehensive source of population-based data in the United States [18] . In the SEER registry, cancers are coded according to the International Classification of Diseases (ICD) for Oncology (third edition) [19] . Beginning in 2000 and beyond, the SEER-17 registries cover 26% of the total USA population. Medicare is the primary health insurer for 97% of the USA population aged ‡65 years. 
chemotherapy
The methods of identifying chemotherapy use through the Medicare claims were discussed elsewhere. In brief, patients were defined as having received chemotherapy if there was a claim for chemotherapy from any of the following Medicare codes that were made 12 months of diagnosis: the ICD-9-CM procedure code of 9925 and V codes of V58.1, V66.2, or V67.2, the Common Procedure Terminology codes of 96400-96549, J8510, J8520, J8521, J8530-J8999, J9000-J9999, and Q0083-Q0085, and revenue center codes of 0331, 0332, and 0335. The use of specific chemotherapy drugs can be ascertained through Common Procedural Terminology J codes in the SEER-Medicare outpatient, physician/supplier, and durable medical equipment files.
Patients who did not receive any i.v. chemotherapy were grouped into the 'no chemo' cohort, patients who received 5-FU alone (J9190) were grouped as '5-FU alone', patients who received chemotherapy containing oxaliplatin (J9263, C9205) were grouped as 'oxaliplatin-based regimens' and patients who received chemotherapy containing bevacizumab (J9035, C9214, and S0116) but no oxaliplatin were grouped into the 'bevacizumabbased regimens'.
adverse events or toxic effects Some selected adverse events or toxic effects were identified through claims in Medicare inpatient, outpatient, and physician/supplier files. We defined the diagnoses of adverse events as demonstrated by at least two different claims >30 days apart after cancer diagnosis that were important to adversely affect the patient's process of care, quality of life (QoL), and survival. Events were included regardless of whether they could be directly attributed to treatment.
Chemotherapy-related toxicity was defined in three ways. First, we evaluated the rates of hospitalization from any cause within 6 months of starting chemotherapy. We carried out a secondary analysis to evaluate hospitalizations within 6 months of chemotherapy initiation with any of the following discharge diagnoses, that indicated chemotherapy associated toxicity: infection (001.0-139.8), neutropenia (288.0), nausea/vomiting (787.0X), dehydration (276.5), diarrhea (787.91), fever (780.6), anemia (284.0-285.9), thrombocytopenia (287.4 and 287.5), delirium (780.X) or drug psychoses (292.X and 293.0.X), pulmonary embolism (415.1) or deep vein thrombosis (671.4), gastroenteritis and colitis (558.2 and 558.9), dermatitis (693.X), acute renal failure (584.X), ischemic heart disease (IHD) (410.X-414.X), congestive heart failure (CHF) (428.X), cardiomyopathy (425.X), conduction disorder (426.X), or cardiac dysrhythmia (427.X). We used a previously published algorithm to identify chemotherapy-associated toxic efffects, which included relevant discharge diagnosis codes in any position. Finally, we evaluated the risk of hospitalization for the individual toxic effects of infection, fever, neutropenia, and anemia.
statistical analysis
The percentage of older patients with CRC receiving chemotherapy and chemotherapy with specific regimens was calculated. Patient age, gender, race/ethnicity, marital status, socioeconomic status, AJCC stage, tumor grade, comorbidity scores, number of positive lymph nodes, primary site-colon/rectal, surgical resection, radiation therapy, SEER registry region, urban/rural residence, and year of diagnosis were included for data analysis. All computer programming and analyses were carried out with the SAS system (SAS Inc., Cary, NC). The cohorts exhibited important differences in baseline characteristics between patients who received i.v. chemotherapy and those who did not receive i.v. chemotherapy. In general, patients who received i.v. chemotherapy were 3-5 years younger at baseline, had more advanced cancer (advanced tumor stages and more positive lymph nodes), had a higher rate of surgical resection and radiation therapy, and were more likely to be married than those who did not receive i.v. chemotherapy. On the other hand, socioeconomic status, gender, colon versus rectal primary tumor type, SEER registry areas, and urban versus rural residence were similar between cohorts.
Over the 3-year period from 2003 to 2005, the numbers of patients who did not receive i.v. chemotherapy were evenly distributed. Compared with patients who received 5-FU alone, patients who received oxaliplatin-based regimen had similar proportion of stage III disease (51% versus 50%), but higher proportion of patients with four or more positive lymph nodes on diagnosis (30% versus 19%) and higher proportion of patients with stage IV disease (29% versus 13%). The proportion of patients receiving oxaliplatin-or bevacizumab-containing . This decrease appears to be caused by oral capecitabine alone replacing 5-FU and other newer agents (oxaliplatin, irinotecan, and bevacizumab) becoming available in the US market during those years. The cumulative incidence (%) of adverse events per cohort is shown in Table 2 (the top half for the entire studied patients with all disease stages and the bottom half for patients with stage I to III diseases only). The data from patients with stage I to III diseases were not much different to the data from the entire studied patients with all disease stages for their cumulative incidence (%) of adverse events. Patients who received i.v. chemotherapy had higher incidences of adverse events in nausea/ vomiting, fever, neutropenia, thrombocytopenia, anemia, dehydration, diarrhea, peripheral neuropathy, gastroenteritis and colitis, delirium or drug psychoses, IHD, and CHF or other non-IHD in comparison to those who did not receive i.v. chemotherapy. Notably, high incidences of symptoms and laboratory test abnormalities were found even in patients who did not receive i.v. chemotherapy. These high incidence rates of symptoms and laboratory test abnormalities were intensified in i.v. chemotherapy-treated elderly patients: infection (increased from 16.2% in no i.v. chemo group to 25.7% in 5-FU alone group), anemia (24%-58.8%), delirium or drug psychoses (24.9%-47.3%), IHD (19.7%-32.3%), CHF, cardiomyopathy, conduction disorder, cardiac dysrhythmia (24.3%-36.4%). The cumulative incidences of adverse events from 5-FU alone and oxaliplatin-based regimens were comparable with higher rates in nausea/vomiting (25.8% versus 42.8%), neutropenia (8.1% versus 27.5%), and neuropathy (1.9% versus 4.5%) from oxaliplatin-based regimens. The cumulative incidences of adverse events from oxaliplatin-based regimens and bevacizumabcontaining regimens (without oxaliplatin) were comparable with higher incidences of neuropathy (1.4% versus 4.5%) from oxaliplatin ( Table 2) .
Using those patients who did not receive i.v. chemotherapy as the referent group, the hazard ratios (HRs) of adverse events in each cohort of patients who received different i.v. chemotherapy regimens are shown in Table 3 (the top half for the entire studied patients with all disease stages, and the bottom half for patients with stage I to III diseases only). Again, the data from patients with stage I to III diseases were comparable to the data from the entire studied patients with all disease stages for their HRs of adverse events from i.v. chemotherapies. Compared with patients who received no i.v. chemotherapy, patients who received 5-FU alone experienced only mildly high rates (HR < 10) of most adverse events except neutropenia with HR of 12. However, patients receiving oxaliplatin-based regimens experienced remarkably higher rates of adverse events, especially for neutropenia (HR = 45), thrombocytopenia (HR = 25), and stomatitis (HR = 13), as Compared with younger elderly patients (aged 65-69 years), the HR of adverse events in older elderly patients (aged ‡70 years) is demonstrated in Table 4 (the top half for the entire studied patients with all stages disease, and the bottom half for patients with stage I to III diseases only). The data from patients with stage I to III diseases were similar to the data from the entire studied patients with all disease stages for HR of adverse events in older Other non-ischemic heart diseases include cardiomyopathy, conduction disorder, or cardiac dysrhythmia. 5-FU, fluorouracil.
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Elderly patients have been underrepresented in clinical trials of treatments of CRC. Hutchins et al. [16] reported that patients who were ‡65 years accounted for only 40% of patients with CRC in clinical trials, in comparison to 72% of those in the US population. Patients who were ‡70 years only accounted for 14% in clinical trials [16] . Physiologic changes of aging, such as increased body fat, reduced total body water, and reduced renal and hepatic function reserves, could lead to pharmacokinetic and pharmacodynamic differences between elderly and younger 1.2 (0.9-1.5) [21] reported that patients with diabetes mellitus receiving 5-FU-based adjuvant chemotherapy experienced a 42% increased risk of death and a 21% increased risk for recurrence in comparison to those without diabetes. Our study found that the cumulative incidence of symptoms and laboratory test abnormalities in patients aged ‡65 are high, even for those who did not receive i.v. chemotherapy; and these high incidences of symptoms and laboratory test abnormalities were further increased after i.v. chemotherapy in these elderly patients. These findings were observed both in patients with localized stage disease receiving adjuvant chemotherapy and in patients with metastatic disease receiving palliative chemotherapy (Tables 2 and 3) .
Our study also showed that oxaliplatin-based regimens lead to higher rates of adverse events compared with 5-FU alone (Tables 2 and 3 ). This was consistent with previous phase III clinical trials findings [6] . The side-effects from 5-FU treatment more tolerable in elderly because of the application of infusional 5-FU in recent years and the practice of using bolus 5-FU had been decreased. Since 2003, several clinical trials had shown that infusional 5-FU was superior to bolus 5-FU in terms of significantly lower toxic effects of neutropenia, diarrhea, stomatitis, nausea, and vomiting [22] [23] [24] [25] .
There is controversy regarding whether chemotherapy-related adverse events in CRC are more common in older patients compared with relatively younger patients (supplementary Table  S1 , available at Annals of Oncology online) [2, 3, 6, 12, 17, 26] . Our study found, in comparison to the younger elderly aged 65-69 years, older elderly patients (aged ‡70 years) had experienced higher adverse events in general ( Table 4 ). The rate of adverse events was age related. This age-related difference in adverse events was regardless which type of chemotherapy regimens they received. Our study had the advantage of a larger sample size. This result was consistent with most authors' findings [2, 3, 6, 12] but was inconsistent with the results of Kahn et al. [17] and Hu et al. [26] studies. These different results may be due to differences in patient selection.
A report from the National Cancer Database (NCDB) between 1990 and 2002 showed that increasing age was associated with decreasing chemotherapy use for stage III nodepositive CRC (80% of patients aged <70 received chemotherapy, 70% of those aged 70-79 years, and 40% of those aged ‡80 years), and adjuvant chemotherapy was beneficial to all age groups [5] . The survival benefit from adding oxaliplatin to 5-FU in elderly patients aged ‡70 years has not been approved in adjuvant chemotherapy setting [9, 10] . Seymour et al. reported a randomized trial for elderly and frail patients (median age 74 years, range, 35-87 years) receiving palliative chemotherapy with 20% reduced dose for CRC. The addition of oxaliplatin increased some toxic effects, negatively affected global (QoL), and did not improve overall survival [27] . Given the lack of long-term survival benefit and increased toxicity in elderly patients, adding oxaliplatin to 5-FU-based adjuvant chemotherapy should be done with caution for elderly patients (aged ‡65 years) with CRC. Moreover, infusional 5-FU as adjuvant chemotherapy should be the standard of treatment of elderly patients who are ‡65 years.
conclusion
The addition of i.v. chemotherapy was associated with higher incidences of symptoms and laboratory test abnormalities in community-dwelling elderly patients with CRC. Patients who received 5-FU alone appeared to have less adverse events than those who received oxaliplatin-based regimens. Patients with ‡70 years tended to experience higher rates of adverse events in comparison to younger patients aged 65-69 years. Further research is needed to understand the association of adverse events and chemotherapy regimens, to identify the patients at risk, to improve patients' selection for chemotherapy, and to provide them better social support and patient education.
